Christopher Raymond
Stock Analyst at Raymond James
(3.42)
# 998
Out of 5,109 analysts
139
Total ratings
53.51%
Success rate
2.53%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics | Initiates: Strong Buy | $25 | $10.58 | +136.29% | 1 | Dec 18, 2025 | |
| ARDX Ardelyx | Maintains: Neutral | $9 → $10 | $5.99 | +66.94% | 10 | Nov 4, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $5.91 | +119.97% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $8.26 | +251.09% | 2 | Oct 21, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $231 → $284 | $229.89 | +23.54% | 13 | Oct 10, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $145.31 | -51.83% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $176.33 | -34.78% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.36 | +561.76% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $60.16 | +109.44% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $3.20 | +25.00% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $535 → $533 | $462.99 | +15.12% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $783.71 | +29.26% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $34.58 | +304.86% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $71.00 | +1.41% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $3.04 | +327.63% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $7.47 | +904.02% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $10.81 | +603.05% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.74 | +1,254.10% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $26.01 | +26.87% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $39.73 | -44.63% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.70 | +135.29% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $333.96 | -13.76% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $29.17 | +40.56% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $46.49 | -39.77% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $105.96 | -62.25% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $5.90 | +1,425.42% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $2.25 | +4,166.67% | 2 | Mar 13, 2020 |
Lexeo Therapeutics
Dec 18, 2025
Initiates: Strong Buy
Price Target: $25
Current: $10.58
Upside: +136.29%
Ardelyx
Nov 4, 2025
Maintains: Neutral
Price Target: $9 → $10
Current: $5.99
Upside: +66.94%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $5.91
Upside: +119.97%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $8.26
Upside: +251.09%
AbbVie
Oct 10, 2025
Maintains: Overweight
Price Target: $231 → $284
Current: $229.89
Upside: +23.54%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $145.31
Upside: -51.83%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $176.33
Upside: -34.78%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.36
Upside: +561.76%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $60.16
Upside: +109.44%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $3.20
Upside: +25.00%
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $462.99
Upside: +15.12%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $783.71
Upside: +29.26%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $34.58
Upside: +304.86%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $71.00
Upside: +1.41%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $3.04
Upside: +327.63%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $7.47
Upside: +904.02%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $10.81
Upside: +603.05%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.74
Upside: +1,254.10%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $26.01
Upside: +26.87%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $39.73
Upside: -44.63%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.70
Upside: +135.29%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $333.96
Upside: -13.76%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $29.17
Upside: +40.56%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $46.49
Upside: -39.77%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $105.96
Upside: -62.25%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $5.90
Upside: +1,425.42%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $2.25
Upside: +4,166.67%